Changes in Hong Kong stocks | Maike Pharmaceutical-B (02335) rose more than 3%, MT200605's phase II clinical trial for acute ischemic stroke reached the main end

The Zhitong Finance App learned that McPharmaceutical-B (02335) rose more than 3%. As of press release, it had risen 3.4% to HK$30.4, with a turnover of HK$20.4952 million.

According to the news, on August 3, Medica Pharmaceutical-B announced that the Phase II clinical trial (this clinical trial) of MT200605, a drug candidate developed independently by the Group to treat AIS, has obtained top-line data. The data shows that the clinical trial has reached its main research endpoint, and the results are statistically significant and clinically significant. In terms of safety, MT200605 was safe and well tolerated. There were no serious adverse events (SAE) associated with the test drug during the entire study period. Adverse events (TEAE) greater than or equal to grade 3 were balanced across groups, and no new significant safety risks were found.

In addition to being used to treat acute ischemic stroke (AIS), MT200605 is also being developed to treat Huntington's Disease (HD). MT200605 can selectively activate the TrkB signaling pathway and exert both neuroprotective and antioxidant effects to protect the structure and function of nervous tissue. Preclinical studies have shown that MT200605 has the potential to directly reduce the aggregation of mutant huntington protein (mHTT), thereby providing a treatment strategy with potential disease-modifying effects for HD. In March 2026, MT200605 was officially certified as an orphan drug by the US Food and Drug Administration (FDA) for HD indications.